PIPE 791
Alternative Names: PIPE-791Latest Information Update: 22 Sep 2025
At a glance
- Originator Pipeline Therapeutics
- Developer Contineum Therapeutics
- Class Analgesics; Anti-inflammatories; Small molecules
- Mechanism of Action Lysophosphatidic acid receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Idiopathic pulmonary fibrosis; Multiple sclerosis; Pain
Most Recent Events
- 18 Sep 2025 Pharmacokinetics and adverse event data from the phase I trial in Multiple sclerosis released by Contineum Therapeutics
- 05 Aug 2025 Contineum Therapeutics announces intention to submit regulatory applications with foreign regulatory authorities, and with the US FDA for Idiopathic pulmonary fibrosis
- 12 Jun 2025 Contineum Therapeutics completes a phase I trial in Idiopathic pulmonary fibrosis in United Kingdom (PO) (NCT06683612)